NADPH Containing Protein Component from Fruits and Plant: Stimulation of NADPH Oxidases of Immune Cells

Author(s):  
R. M. Simonyan ◽  
K. V. Simonyan ◽  
S. M. Feschyan ◽  
V. A. Chavushyan ◽  
G. M. Simonyan ◽  
...  
2014 ◽  
Vol 136 (31) ◽  
pp. 10823-10825 ◽  
Author(s):  
Keun Ah Ryu ◽  
Lalisa Stutts ◽  
Janine K. Tom ◽  
Rock J. Mancini ◽  
Aaron P. Esser-Kahn

2021 ◽  
Vol 3 (1) ◽  
pp. 1-12
Author(s):  
Muhammad Mikail Athif Zhafir Asyura ◽  
Ahmad Fauzi ◽  
Fakhru Adlan Ayub

Introduction: Dengue Virus (DENV) is the pathogen for human dengue fever and is responsible for 390 million infections per year. The viral genome produces about 10 viral protein products, one of them being NS1. The NS1 protein plays a key role in viral replication and stimulation of humoral immune cells, thus being the perfect candidate to create an effective antiviral drug or vaccine for dengue Methods: Dengue Virus (DENV) is the pathogen for human dengue fever and is responsible for 390 million infections per year. The viral genome produces about 10 viral protein products, one of them being NS1. The NS1 protein plays a key role in viral replication and stimulation of humoral immune cells, thus being the perfect candidate to create an effective antiviral drug or vaccine for dengue Conclusion: The review established promising results of using peptide-based intervention on NS1. Further in vivo and randomized controlled trials are advised to solidify the applicability and biosafety of the intervention    


2012 ◽  
Vol 5 (1) ◽  
pp. 229 ◽  
Author(s):  
Gang Chen ◽  
Maiara S Severo ◽  
Mohammad Sohail ◽  
Olivia S Sakhon ◽  
Stephen K Wikel ◽  
...  

Pharmaceutics ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 30 ◽  
Author(s):  
Michael Lim ◽  
Abu Zayed Md Badruddoza ◽  
Jannatul Firdous ◽  
Mohammad Azad ◽  
Adnan Mannan ◽  
...  

DNA vaccines offer a flexible and versatile platform to treat innumerable diseases due to the ease of manipulating vaccine targets simply by altering the gene sequences encoded in the plasmid DNA delivered. The DNA vaccines elicit potent humoral and cell-mediated responses and provide a promising method for treating rapidly mutating and evasive diseases such as cancer and human immunodeficiency viruses. Although this vaccine technology has been available for decades, there is no DNA vaccine that has been used in bed-side application to date. The main challenge that hinders the progress of DNA vaccines and limits their clinical application is the delivery hurdles to targeted immune cells, which obstructs the stimulation of robust antigen-specific immune responses in humans. In this updated review, we discuss various nanodelivery systems that improve DNA vaccine technologies to enhance the immunological response against target diseases. We also provide possible perspectives on how we can bring this exciting vaccine technology to bedside applications.


Blood ◽  
2014 ◽  
Vol 124 (25) ◽  
pp. 3675-3684 ◽  
Author(s):  
Francesca S. Gazzaniga ◽  
Elizabeth H. Blackburn

Key Points Telomerase RNA component hTR, but not the core enzymatic protein component hTERT, protects T cells from apoptosis. hTR prevents dexamethasone-induced apoptosis specifically when in a telomerase enzymatically inactive state.


eLife ◽  
2018 ◽  
Vol 7 ◽  
Author(s):  
Eva Plesch ◽  
Cheng-Chang Chen ◽  
Elisabeth Butz ◽  
Anna Scotto Rosato ◽  
Einar K Krogsaeter ◽  
...  

Cytokines and chemokines are produced and secreted by a broad range of immune cells including macrophages. Remarkably, little is known about how these inflammatory mediators are released from the various immune cells. Here, the endolysosomal cation channel TRPML2 is shown to play a direct role in chemokine trafficking and secretion from murine macrophages. To demonstrate acute and direct involvement of TRPML2 in these processes, the first isoform-selective TRPML2 channel agonist was generated, ML2-SA1. ML2-SA1 was not only found to directly stimulate release of the chemokine CCL2 from macrophages but also to stimulate macrophage migration, thus mimicking CCL2 function. Endogenous TRPML2 is expressed in early/recycling endosomes as demonstrated by endolysosomal patch-clamp experimentation and ML2-SA1 promotes trafficking through early/recycling endosomes, suggesting CCL2 being transported and secreted via this pathway. These data provide a direct link between TRPML2 activation, CCL2 release and stimulation of macrophage migration in the innate immune response.


2021 ◽  
Vol 7 ◽  
Author(s):  
Caroline Ruetsch ◽  
Vesna Brglez ◽  
Marion Crémoni ◽  
Kévin Zorzi ◽  
Céline Fernandez ◽  
...  

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan in December 2019 and has since spread across the world. Even though the majority of patients remain completely asymptomatic, some develop severe systemic complications. In this prospective study we compared the immunological profile of 101 COVID-19 patients with either mild, moderate or severe form of the disease according to the WHO classification, as well as of 50 healthy subjects, in order to identify functional immune factors independently associated with severe forms of COVID-19. Plasma cytokine levels, and cytokine levels upon in vitro non-specific stimulation of innate and adaptive immune cells, were measured at several time points during the course of the disease. As described previously, inflammatory cytokines IL1β, IL6, IL8, and TNFα associated with cytokine storm were significantly increased in the plasma of moderate and severe COVID-19 patients (p < 0.0001 for all cytokines). During follow-up, plasma IL6 levels decreased between the moment of admission to the hospital and at the last observation carried forward for patients with favorable outcome (p = 0.02148). After in vitro stimulation of immune cells from COVID-19 patients, reduced levels of both type I and type II interferons (IFNs) upon in vitro stimulation were correlated with increased disease severity [type I IFN (IFNα): p > 0.0001 mild vs. moderate and severe; type II IFN (IFNγ): p = 0.0002 mild vs. moderate and p < 0.0001 mild vs. severe] suggesting a functional exhaustion of IFNs production. Stimulated IFNα levels lower than 2.1 pg/ml and IFNγ levels lower than 15 IU/mL at admission to the hospital were associated with more complications during hospitalization (p = 0.0098 and p =0.0002, respectively). A low IFNγ level was also confirmed by multivariable analysis [p = 0.0349 OR = 0.98 (0.962; 0.999)] as an independent factor of complications. In vitro treatment with type IFNα restored type IFNγ secretion in COVID-19 patients while the secretion of pro-inflammatory cytokines IL6 and IL1β remained stable or decreased, respectively. These results (a) demonstrate a functional exhaustion of both innate and adaptive immune response in severe forms of COVID-19; (b) identify IFNα and IFNγ as new potential biomarkers of severity; and (c) highlight the importance of targeting IFNs when considering COVID-19 treatment in order to re-establish a normal balance between inflammatory and Th1 effector cytokines.


Sign in / Sign up

Export Citation Format

Share Document